Intellia Therapeutics, Inc. (NTLA) stock
NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 3/3025% above fair value
$9.70−0.85 (-8.06%)
Close on Nov 13, 2026Market cap $1.36BP/E –Yield –
Intellia Therapeutics statistics
79 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.
Important dates
- Next earnings
- Feb 25, 2027 (estimated, before the open)
- Last ex-dividend date
- No dividends
- Fundamentals through
- Sep 30, 2026
- Share price as of
- Nov 13, 2026
Valuation ratiosIndustry
- P/TBV Ratio
- 2.22
- 2.22
Enterprise valuationIndustry
- EV / Sales
- 18.13
- 2.57
Share statisticsIndustry
- Shares Change (YoY)
- 21.2%
- 10.8%
- Shares Change (QoQ)
- 0.17%
- 0.50%
- Float
- 137M
- 49M
- Shares Held by Insiders
- 2.00%
- 11.7%
- Shares Held by Institutions
- 102.8%
- 56.4%
Short sellingIndustry
- Short Interest
- 44M
- –
- Short Interest Change
- -0.17%
- -0.80%
- Short % of Float
- 32.3%
- 9.01%
- Short % of Shares Outstanding
- 31.7%
- 6.30%
- Days to Cover
- 11.05
- 5.15
Stock price statisticsIndustry
- 52-Week High
- $18.48
- –
- 52-Week Low
- $7.95
- –
- 20-Day Moving Average
- $11.66
- –
- 50-Day Moving Average
- $11.92
- –
- 200-Day Moving Average
- $12.96
- –
- Average True Range (14)
- $0.85
- –
- Price Change (1 Week)
- -14.5%
- -1.15%
- Price Change (1 Month)
- -14.5%
- -4.87%
- Price Change (3 Months)
- -19.8%
- -21.0%
- Price Change (6 Months)
- -29.0%
- -20.6%
- Price Change (YTD)
- 7.90%
- -23.6%
- Price Change (1 Year)
- 2.21%
- -22.4%
- Price Change (3 Years)
- -63.3%
- -29.5%
- Price Change (5 Years)
- -92.7%
- -77.9%
- Price Change (10 Years)
- -40.3%
- -65.4%
- Average Volume (10 Days)
- 5M
- –
- Average Volume (20 Days)
- 4M
- –
- Average Volume (90 Days)
- 4M
- –
- Relative Volume
- 2.62
- 0.70
- Relative Strength Index (14)
- 36.4
- 43.4
- Volatility (1 Year)
- 76.4%
- 80.1%
- Beta (5 Years)
- 2.08
- 1.07
MarginsIndustry
- EBITDA Margin
- -805.0%
- -27.7%
- FCF Margin
- -677.1%
- -9.56%
Returns on capitalIndustry
- Return on Equity (ROE)
- -62.6%
- -49.9%
- Return on Assets (ROA)
- -46.6%
- -40.6%
- Return on Invested Capital (ROIC)
- -152.5%
- -32.9%
- Return on Capital Employed (ROCE)
- -52.8%
- -37.9%
Financial positionIndustry
- Current Ratio
- 6.31
- 3.30
- Quick Ratio
- 6.00
- 2.39
- Debt / Equity
- 0.12
- 0.49
GrowthIndustry
- Revenue Growth (YoY)
- -8.07%
- 6.82%
- Revenue Growth (3Y CAGR)
- 9.09%
- 2.25%
- Revenue Growth (5Y CAGR)
- 3.13%
- 6.41%
EfficiencyIndustry
- Asset Turnover
- 0.06
- 0.40
- Revenue Per Employee
- $140.28K
- $429.29K
- Profits Per Employee
- -$1.13M
- -$689.41K
- Employee Count
- 377
- 74
- WACC
- 15.0%
- 10.2%
Income statement (TTM)Industry
Balance sheetIndustry
- Net Cash (Debt)
- $400.38M
- $17.76M
- Net Cash Per Share
- $2.86
- $0.80
- Equity (Book Value)
- $613.09M
- $53.89M
- Book Value Per Share
- $4.38
- $1.50
- Tangible Book Value
- $613.09M
- $27.13M
- Working Capital
- $426.04M
- $79.99M
Cash flow (TTM)Industry
- Capital Expenditures
- -$2.90M
- -$1.00M
- FCF Per Share
- -$2.56
- -$0.42
Dividends and yieldsIndustry
- Earnings Yield
- -31.4%
- -21.8%
- FCF Yield
- -26.3%
- -9.44%
Scores and fair valueIndustry
- Altman Z-Score
- -2.68
- 0.23
- Piotroski F-Score
- 3
- 4
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | NTLA | S&P 500 | Difference | NTLA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -18.6% | -3.0% | −15.5 pts | ||
| 3 months | -18.0% | -2.8% | −15.2 pts | ||
| Year to date | +7.9% | +11.5% | −3.6 pts | ||
| 1 year | +11.9% | +13.5% | −1.6 pts | ||
| 3 years | -59.3% | +77.7% | −137.0 pts | -25.9% | +21.1% |
| 5 years | -92.7% | +72.6% | −165.3 pts | -40.7% | +11.5% |
| 10 years | -34.5% | +308.2% | −342.6 pts | -4.1% | +15.1% |
Short interest
Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.
44M NTLA shares were sold short on Oct 30, 2026, down 0.2% from the previous report, or 32.31% of the shares available to trade. At recent volumes it would take 11.1 days to buy them back. Over the last 20 sessions, 48.0% of the volume reported to FINRA was short selling.
| Settlement date | Shares short | Change | Avg. daily volume | Days to cover |
|---|---|---|---|---|
| Oct 30, 2026 | 44,361,762 | -0.2% | 4,013,427 | 11.1 |
| Oct 15, 2026 | 44,435,219 | -1.5% | 6,891,382 | 6.5 |
| Sep 30, 2026 | 45,110,513 | -3.4% | 4,765,594 | 9.5 |
| Sep 15, 2026 | 46,681,609 | +6.3% | 3,311,168 | 14.1 |
| Aug 31, 2026 | 43,928,014 | -2.1% | 3,408,436 | 12.9 |
| Aug 14, 2026 | 44,880,339 | +2.0% | 3,412,934 | 13.2 |
| Jul 31, 2026 | 44,010,769 | -3.9% | 3,680,746 | 12.0 |
| Jul 15, 2026 | 45,776,294 | -7.0% | 4,694,333 | 9.8 |
| Jun 30, 2026 | 49,218,272 | -2.2% | 6,528,309 | 7.5 |
| Jun 15, 2026 | 50,318,535 | +3.7% | 6,743,092 | 7.5 |
| May 29, 2026 | 48,516,271 | -6.4% | 5,256,351 | 9.2 |
| May 15, 2026 | 51,849,425 | +19.1% | 6,755,199 | 7.7 |
Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.
See a number that looks wrong?